MAC
VRTX icon

Mason & Associates (California)’s Vertex Pharmaceuticals VRTX Stock Holding History

Mason & Associates (California)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-665
Closed -$301K – 171
2025
Q4 		$301K Buy
665
+10
+2% +$4.31K 0.06% 137
2025
Q3 		$257K Buy
+655
New +$274K 0.05% 117
2022
Q3 		– Sell
-1,097
Closed -$309K – 87
2022
Q2 		$309K Hold
1,097
– – 0.11% 67
2022
Q1 		$286K Hold
1,097
– – 0.09% 91
2021
Q4 		$241K Buy
+1,097
New +$213K 0.07% 89

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Mason & Associates (California)'s VRTX Position: Q1 2026 in Review

Mason & Associates (California) sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 665 shares — an estimated $301K sold.

Mason & Associates (California) first reported a position in VRTX in Q4 2021 and held it in 5 quarters. The position peaked at $309K in Q2 2022. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Mason & Associates (California) reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mason & Associates (California) sold 665 Vertex Pharmaceuticals shares in Q1 2026, an estimated $301K.
  • Mason & Associates (California) first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Mason & Associates (California)'s Vertex Pharmaceuticals position peaked at $309K in Q2 2022.
  • 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Mason & Associates (California)'s 13F filing for Q1 2026, filed 30 Apr 2026.